BACKGROUND: Entecavir, an antiviral with potent anti-hepatitis B virus activity, was recently shown to have anti-HIV activity in three patients and the ability to select for the lamivudine-resistant HIV polymerase mutation M184V in a patient with prior antiretroviral therapy. OBJECTIVES: To further characterize entecavir's anti-HIV activity and identify risk factors for selection of the M184V. DESIGN: Retrospective cohort study. METHODS: We evaluated the virological characteristics of HIV and hepatitis B virus in 17 HIV-hepatitis B virus coinfected patients (10 antiretroviral therapy-naive and seven antiretroviral therapy-experienced) prior to and during entecavir monotherapy. Descriptive statistics were used to assess changes in HIV RNA and hepatitis B virus DNA. Variables associated with development of the M184V were determined by univariate analysis. RESULTS: Of the 17 patients, 13 (76%) demonstrated a reduction in HIV RNA by at least 0.5 log10 copies/ml. Of the remaining four patients, two had the M184V detected prior to entecavir therapy and the other two had wild-type HIV. The median reduction in HIV RNA for the cohort was 1.2 log10 copies/ml, which was similar in antiretroviral therapy-naive and antiretroviral therapy-experienced patients. The M184V mutation emerged in six patients receiving entecavir, including three antiretroviral therapy-naive patients. No other HIV mutations were consistently detected. Risk factors for the emergence of the M184V mutation were a decline in hepatitis B virus DNA (P = 0.04) and duration of entecavir use (P = 0.05). CONCLUSION: Entecavir monotherapy in HIV-hepatitis B virus coinfected patients, including antiretroviral therapy-naive patients, has significant anti-HIV activity and can result in the development of the M184V variant. Entecavir should not be used in such co-infected patients without concomitant antiretroviral therapy.
BACKGROUND:Entecavir, an antiviral with potent anti-hepatitis B virus activity, was recently shown to have anti-HIV activity in three patients and the ability to select for the lamivudine-resistant HIV polymerase mutation M184V in a patient with prior antiretroviral therapy. OBJECTIVES: To further characterize entecavir's anti-HIV activity and identify risk factors for selection of the M184V. DESIGN: Retrospective cohort study. METHODS: We evaluated the virological characteristics of HIV and hepatitis B virus in 17 HIV-hepatitis B virus coinfectedpatients (10 antiretroviral therapy-naive and seven antiretroviral therapy-experienced) prior to and during entecavir monotherapy. Descriptive statistics were used to assess changes in HIV RNA and hepatitis B virus DNA. Variables associated with development of the M184V were determined by univariate analysis. RESULTS: Of the 17 patients, 13 (76%) demonstrated a reduction in HIV RNA by at least 0.5 log10 copies/ml. Of the remaining four patients, two had the M184V detected prior to entecavir therapy and the other two had wild-type HIV. The median reduction in HIV RNA for the cohort was 1.2 log10 copies/ml, which was similar in antiretroviral therapy-naive and antiretroviral therapy-experienced patients. The M184V mutation emerged in six patients receiving entecavir, including three antiretroviral therapy-naive patients. No other HIV mutations were consistently detected. Risk factors for the emergence of the M184V mutation were a decline in hepatitis B virus DNA (P = 0.04) and duration of entecavir use (P = 0.05). CONCLUSION:Entecavir monotherapy in HIV-hepatitis B virus coinfectedpatients, including antiretroviral therapy-naive patients, has significant anti-HIV activity and can result in the development of the M184V variant. Entecavir should not be used in such co-infected patients without concomitant antiretroviral therapy.
Authors: S F Innaimo; M Seifer; G S Bisacchi; D N Standring; R Zahler; R J Colonno Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.938
Authors: Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245
Authors: J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin Journal: N Engl J Med Date: 1995-12-21 Impact factor: 91.245
Authors: C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari Journal: J Clin Invest Date: 1998-09-01 Impact factor: 14.808
Authors: M S Saag; A Sonnerborg; R A Torres; D Lancaster; B G Gazzard; R T Schooley; C Romero; D Kelleher; W Spreen; S LaFon Journal: AIDS Date: 1998-11-12 Impact factor: 4.177
Authors: G Yamanaka; T Wilson; S Innaimo; G S Bisacchi; P Egli; J K Rinehart; R Zahler; R J Colonno Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.938
Authors: Albert M Anderson; Marina B Mosunjac; Melody P Palmore; Melissa K Osborn; Andrew J Muir Journal: World J Gastroenterol Date: 2010-08-28 Impact factor: 5.742
Authors: Noortje M van Maarseveen; Annemarie Mj Wensing; Dorien de Jong; Greg L Beilhartz; Aleksandr Obikhod; Sijia Tao; Marieke Pingen; Joop E Arends; Andy Im Hoepelman; Raymond F Schinazi; Matthias Götte; Monique Nijhuis Journal: Antivir Ther Date: 2011
Authors: A Antinori; A Ammassari; C Torti; P Marconi; M Andreoni; G Angarano; S Bonora; A Castagna; R Cauda; M Clerici; A d'Arminio Monforte; A De Luca; G Di Perri; M Galli; E Girardi; A Gori; A Lazzarin; S Lo Caputo; F Mazzotta; F Montella; C Mussini; C F Perno; M Puoti; G Rizzardini; S Rusconi; V Vullo; G Carosi Journal: Infection Date: 2009-05-28 Impact factor: 3.553